3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA
Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Financial Results, Press Release
Inhibikase Therapeutics Files $185 Million Prospectus Supplement for ATM Program
Inhibikase Therapeutics Enters Underwriting Agreement for Public Offering
Investor Presentation
Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Submission of Matters to a Vote of Security Holders
Q3
Q2
Q1
Amended Annual Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence